

Clinical Trial Protocol

Iranian Registry of Clinical Trials

10 Jun 2026

Investigating the effect of adding L-carnitine supplement to migraine prophylaxis treatment on the symptoms and signs of migraine headaches.

Protocol summary

Study aim

Investigating the effect of adding L-carnitine supplement to migraine prophylaxis treatment on the symptoms and signs of migraine headaches in patients referred to the neurology clinic of Allameh Bohloul Gonabadi Hospital.

Design

Parallel group, double blind, randomized controlled trial in phase 2 and sample size of 48. Randomization was done using permutation block with size of 4.

Settings and conduct

This interventional study will be conducted as a prospective, Single-center trial. 48 patients with migraine admitted to Bohloul hospital will be selected. All patients who meet the eligibility criteria with informed consent will receive l-carnitin or placebo. The control and intervention groups are marked with two codes A and B, and the outcome evaluation physician and the analyst will not be aware of the nature of these two groups for data analysis.

Participants/Inclusion and exclusion criteria

Inclusion criteria :Informed consent, Migraine with or without aura, Having 2 or more migraine attacks per month. Exclusion criteria: Absence of kidney or liver disease, Pregnancy, breastfeeding.

Intervention groups

The intervention group and control group includes patients with migraine. The intervention group was treated for one month with the standard migraine prophylaxis treatment + 500 mg L-carnitine tablets of Kharazmi company, crushed and placed inside the capsule, one daily. In the control group, capsules with the same color and shape as the test group are added once a day to routine migraine prophylaxis treatment for one month.

Main outcome variables

Number of days with moderate to severe headache lasting more than 4 hours or treated with usual

treatments, Severity of headache on days with headache, Doses of analgesics and triptans

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20200418047116N3**

Registration date: **2023-09-10, 1402/06/19**

Registration timing: **prospective**

Last update: **2023-09-10, 1402/06/19**

Update count: **0**

Registration date

2023-09-10, 1402/06/19

Registrant information

Name

Negar Shafaei bajestani

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 51 5723 6833

Email address

shafaei.n@gmu.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2023-09-23, 1402/07/01

Expected recruitment end date

2024-03-05, 1402/12/15

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date
empty

Scientific title
Investigating the effect of adding L-carnitine supplement to migraine prophylaxis treatment on the symptoms and signs of migraine headaches.

Public title
Investigating the effect of adding L-carnitine supplement to migraine prophylaxis treatment

Purpose
Prevention

Inclusion/Exclusion criteria
Inclusion criteria:
Signed informed consent Migraine with or without aura according to the International Classification of Headache Disorders Having 2 or more migraine attacks per month during the past 3 months Migraine onset before age 50 BMI (kg/m²) between 18 and 35
Exclusion criteria:
Absence of kidney disease or reduced kidney function and liver cirrhosis No previous use of L-carnitine No use of ≥ 3 prophylactic medications against migraine during the past 5 years No alcohol or illegal drug addiction Not having asthma or vascular disease, arterial lameness Pregnancy, breastfeeding

Age
From **18 years** old to **65 years** old

Gender
Both

Phase
3

Groups that have been masked

- Participant
- Outcome assessor
- Data analyser

Sample size
Target sample size: **48**

Randomization (investigator's opinion)
Randomized

Randomization description
In the current study, patients with migraine referred to the neurology clinic of Allameh Bohloul Gonabadi Hospital were selected using available sampling technique. If they want to participate in the study and meet the entry criteria, written and informed consent will be obtained from them. Then, in order to assign the patients to two intervention and control groups, he used the method of quadruple permutation blocks in such a way that first six possible states of the blocks (BAAB, ABBA, BABA, BBAA, ABAB, AABB) were listed and to each block one number of One to six will be allocated and will be used for four patients. Then, a number between one and six is randomly selected using the random number table, and then people are assigned to the control group (A) and the intervention group (B) based on the block corresponding to the selected number. It will continue until the end of the sample size.

Blinding (investigator's opinion)

Double blinded

Blinding description
In the intervention group, L-carnitine tablets of 500 mg once a day will be crushed and placed inside the capsule and will be added to the routine migraine prophylaxis treatment. . In the control group, routine prophylaxis treatment and identical placebo are used instead of L-carnitine. People in both the intervention and control groups will receive the necessary training from the researcher about the objectives of the study, the benefits of studying how and how much to consume L-carnitine, the exclusion criteria, and the duration of the intervention. did The control and intervention groups are marked with two codes A and B, and the outcome evaluation physician and the analyst will not be aware of the nature of these two groups for data analysis.

Placebo
Used

Assignment
Parallel

Other design features

Secondary Ids
empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics committee of Gonabad University of Medical Sciences
Street address
Imam Khomeini Street, Gonabad University of Medical Sciences
City
Gonabad
Province
Razavi Khorasan
Postal code
9691615147

Approval date
2023-01-09, 1401/10/19

Ethics committee reference number
IR.GMU.REC.1401.194

Health conditions studied

1

Description of health condition studied
Migraine
ICD-10 code
G43.9
ICD-10 code description
Migraine, unspecified

Primary outcomes

1

Description

Number of days with moderate to severe headache lasting more than 4 hours or treated with usual treatments

Timepoint

Before the intervention and 4 and 8 weeks after the intervention

Method of measurement

check list

Secondary outcomes

1

Description

Number of days with migraine

Timepoint

Before the intervention and 4 and 8 weeks after the intervention

Method of measurement

check list

2

Description

Severity of headache on days with headache

Timepoint

Before the intervention and 4 and 8 weeks after the intervention

Method of measurement

MIGSEV scale

3

Description

Doses of analgesics and triptans

Timepoint

Before the intervention and 4 and 8 weeks after the intervention

Method of measurement

check list

Intervention groups

1

Description

Intervention group: L-carnitine 500 mg tablets of Kharazmi Company are crushed and placed inside the capsule and taken once a day orally for one month to be added to the routine migraine prophylaxis treatment.

Category

Prevention

2

Description

Control group: Capsules similar to the intervention group containing 10 mg of starch once a day orally for one month will be added to the routine migraine prophylaxis treatment.

Category

Prevention

Recruitment centers

1

Recruitment center

Name of recruitment center

neurology clinic of Allameh Bohloul Gonabadi Hospital

Full name of responsible person

Negar shafaei bajestani

Street address

Imam Khomeini Street, Gonabad University of Medical Sciences

City

Gonabad

Province

Razavi Khorasan

Postal code

9691615147

Phone

+98 51 5722 3514

Email

info@gmu.ac.ir

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Gonabad University of Medical Sciences

Full name of responsible person

Leila Sadegh Moghadam

Street address

Imam Khomeini Street, Gonabad University of Medical Sciences

City

Gonabad

Province

Razavi Khorasan

Postal code

9691615137

Phone

+98 51 5722 3513

Email

info@gmu.ac.ir

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Gonabad University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Gonabad University of Medical Sciences

Full name of responsible person

Negar Shafaei Bajestani

Position

Assistant Professor

Latest degree

Specialist

Other areas of specialty/work

Medical Pharmacy

Street address

Allameh Bohlool Gonabadi Hospital, Vahdat Blvd., Saadi St.

City

Gonabad

Province

Razavi Khorasan

Postal code

9691797852

Phone

+98 51 5723 6833

Email

negar.shafaei89@gmail.com

Person responsible for scientific inquiries

Contact

Name of organization / entity

Gonabad University of Medical Sciences

Full name of responsible person

Negar Shafaei bajestani

Position

Assistant Professor

Latest degree

Specialist

Other areas of specialty/work

Medical Pharmacy

Street address

Saadi St., Vahdat Blvd., Allameh Bohlool Gonabadi Hospital

City

Gonabad

Province

Razavi Khorasan

Postal code

9691797852

Phone

+98 51 5723 6833

Fax

Email

negar.shafaei89@gmail.com

Person responsible for updating data

Contact

Name of organization / entity

Gonabad University of Medical Sciences

Full name of responsible person

Negar Shafaei bajestani

Position

Assistant Professor

Latest degree

Specialist

Other areas of specialty/work

Medical Pharmacy

Street address

Saadi St., Vahdat Blvd., Allameh Bohlool Gonabadi Hospital

City

Gonabad

Province

Razavi Khorasan

Postal code

9691797852

Phone

+98 51 5723 6833

Fax

Email

negar.shafaei89@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Yes - There is a plan to make this available

Study Protocol

Yes - There is a plan to make this available

Statistical Analysis Plan

Yes - There is a plan to make this available

Informed Consent Form

Yes - There is a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

Yes - There is a plan to make this available

Data Dictionary

Not applicable

Title and more details about the data/document

All data can be shared after patients are made unidentifiable.

When the data will become available and for how long

Data can be accessible 6 months after results are published

To whom data/document is available

The researchers in university and other scientific institutes.

Under which criteria data/document could be used

Applications can be submitted for any project that is useful for the treatment of patients.

From where data/document is obtainable

Data can be accessible through sending an email to the corresponding author. negar.shafaei@mail.com

What processes are involved for a request to access data/document

After sending a request email to the corresponding

author, data will be sent in 1 month.

Comments